Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.

@article{Gallamini2011EarlyCI,
  title={Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.},
  author={Andrea Gallamini and Caterina Patti and Simonetta Viviani and Andrea Rossi and Francesca Fiore and Francesco Di Raimondo and Maria Cantonetti and Caterina Stelitano and Tatyana Feldman and Paolo Gavarotti and Roberto Sorasio and Antonino Mul{\'e} and Monica Leone and Alessandro Rambaldi and Alberto Biggi and Sally Barrington and Federico Fallanca and Umberto Ficola and St{\'e}phane Chauvie and Alessandro Massimo Gianni},
  journal={British journal of haematology},
  year={2011},
  volume={152 5},
  pages={
          551-60
        }
}
  • Andrea Gallamini, Caterina Patti, +17 authors Alessandro Massimo Gianni
  • Published in
    British journal of…
    2011
  • Medicine
  • UNLABELLED Interim 2-[18F]Fluoro-2-deoxy-D-glucose Positron Emission Tomography performed after two chemotherapy cycles (PET-2) is the most reliable predictor of treatment outcome in ABVD-treated Hodgkin Lymphoma (HL) patients. We retrospectively analysed the treatment outcome of a therapeutic strategy based on PET-2 results: positive patients switched to BEACOPP, while negative patients continued with ABVD. Between January 2006 and December 2007, 219 newly diagnosed HL patients admitted to… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 72 CITATIONS, ESTIMATED 53% COVERAGE

    "Pet negativity"--the new goal of cytoreductive therapy in Hodgkin's lymphoma?

    • John William Sweetenham
    • Medicine
    • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
    • 2011
    VIEW 4 EXCERPTS
    CITES BACKGROUND & METHODS
    HIGHLY INFLUENCED

    Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.

    VIEW 1 EXCERPT

    Focus On 1 : Emerging Paradigms in PET

    Imaging in Clinical Oncology

    VIEW 1 EXCERPT
    CITES BACKGROUND

    FILTER CITATIONS BY YEAR

    2011
    2019

    CITATION STATISTICS

    • 2 Highly Influenced Citations

    • Averaged 7 Citations per year from 2017 through 2019